G-protein coupled receptor 5C (GPRC5C) is required for osteoblast differentiation and responds to EZH2 inhibition and multiple osteogenic signals

Dashti, Parisa<sup>1</sup>; Thaler, Roman<sup>1</sup>; Hawse, John R.<sup>2</sup>; Galvan, M. Lizeth<sup>1</sup>; van der Eerden, Bram J.<sup>3</sup>; van Wijnen, Andre J.<sup>3,4</sup>; Dudakovic, Amel<sup>1,2</sup>

Affiliations

¹Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, USA

²Department of Biochemistry & Molecular Biology, Mayo Clinic, Rochester, MN, USA

³Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands

⁴Department of Biochemistry, University of Vermont, Burlington, VT, USA

Abstract

Osteoblast differentiation is epigenetically suppressed by the H3K27 methyltransferase EZH2, and induced by the morphogen BMP2 and transcription factor RUNX2. These factors also regulate distinct G protein coupled receptors (GPRCs; e.g., PTH1R, GPR30/GPER1). Because GPRCs transduce many physiological stimuli, we examined whether BMP2 or EZH2 inhibition (i.e., GSK126) regulates other GPRC genes in osteoblasts. RNA-seq screening of >400 mouse GPRC-related genes showed that many GPRCs are downregulated during osteogenic differentiation. The orphan receptor GPRC5C, along with a small subset of other GPRCs, is induced by BMP2 or GSK126 during Vitamin C dependent osteoblast differentiation, but not by all-trans retinoic acid. ChIP-seq analysis revealed that GSK126 reduces H3K27me3 levels at the GPRC5C gene locus in differentiating MC3T3-E1 osteoblasts, consistent with enhanced GPRC5C mRNA expression. Loss of function analyses revealed that shRNA-mediated depletion of GPRC5C decreases expression of bone markers (e.g., BGLAP and IBSP) and mineral deposition in response to BMP2 or GSK126. GPRC5C mRNA was found to be reduced in the osteopenic bones of KLF10 null mice which have compromised BMP2 signaling. GPRC5C mRNA is induced by the bone-anabolic activity of 17β-estradiol in trabecular but not cortical bone following ovariectomy. Collectively, these findings suggest that GPRC5C protein is a key node in a pro-osteogenic axis that is normally suppressed by EZH2-mediated H3K27me3 marks and induced during osteoblast differentiation by GSK126, BMP2, and/or 17β-estradiol. Because GPRC5C protein is an understudied orphan receptor required for osteoblast differentiation, identification of ligands that induce GPRC5C signaling may support therapeutic strategies to mitigate bone-related disorders.

Links

DOI: 10.1016/j.bone.2023.116866

PubMed: 37558192

WoS: 001066135200001

History

Received: 2023-05-16

Revised: 2023-07-24

Accepted: 2023-08-3

Online: 2023-08-7

Cited Works (7)

Year	Entry
2016	Black DM, Rosen CJ. Postmenopausal osteoporosis. NEJM. January 21, 2016;374(3):254-262.
2020	Sen B, Paradise CR, Xie Z, Sankaran J, Uzer G, Styner M, Meyer M, Dudakovic A, van Wijnen AJ, Rubin J. Β‐catenin preserves the stem state of murine bone marrow stromal cells through activation of EZH2. J Bone Miner Res. June 2020;35(6):1149-1162.
2021	van Wijnen AJ, Bagheri L, Badreldin AA, Larson AN, Dudakovic A, Thaler R, Paradise CR, Wu Z. Biological functions of chromobox (CBX) proteins in stem cell self-renewal, lineage-commitment, cancer and development. Bone. February 2021;143:115659.
1988	Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM, Wang EA. Novel regulators of bone formation: molecular clones and activities. Science. December 16, 1988;242(4885):1528-1534.
2022	Paradise CR, Galvan ML, Pichurin O, Jerez S, Kubrova E, Dehghani SS, Carrasco ME, Thaler R, Larson AN, van Wijnen AJ, Dudakovic A. Brd4 is required for chondrocyte differentiation and endochondral ossification. Bone. January 2022;154:116234.
2020	Ideno H, Nakashima K, Komatsu K, Araki R, Abe M, Arai Y, Kimura H, Shinkai Y, Tachibana M, Nifuji A. G9a is involved in the regulation of cranial bone formation through activation of Runx2 function during development. Bone. August 2020;137:115332.
2021	Galvan ML, Paradise CR, Kubrova E, Jerez S, Khani F, Thaler R, Dudakovic A, van Wijnen AJ. Multiple pharmacological inhibitors targeting the epigenetic suppressor enhancer of zeste homolog 2 (Ezh2) accelerate osteoblast differentiation. Bone. September 2021;150:115993.